CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 119 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,000,500 | -19.7% | 183,257 | +17.0% | 0.00% | -50.0% |
| Q2 2023 | $4,980,158 | +14.3% | 156,658 | -12.3% | 0.00% | +100.0% |
| Q1 2023 | $4,355,445 | -16.4% | 178,575 | +8.1% | 0.00% | -50.0% |
| Q4 2022 | $5,208,453 | +866.3% | 165,138 | +765.5% | 0.00% | – |
| Q3 2022 | $539,000 | -61.1% | 19,081 | -63.6% | 0.00% | -100.0% |
| Q2 2022 | $1,387,000 | +7.4% | 52,424 | +42.1% | 0.00% | – |
| Q1 2022 | $1,291,000 | -81.2% | 36,895 | -82.5% | 0.00% | -100.0% |
| Q4 2021 | $6,853,000 | +2720.2% | 211,382 | +2471.6% | 0.00% | – |
| Q3 2021 | $243,000 | +45.5% | 8,220 | +26.5% | 0.00% | – |
| Q2 2021 | $167,000 | +45.2% | 6,500 | -22.6% | 0.00% | – |
| Q1 2021 | $115,000 | -48.2% | 8,403 | -37.2% | 0.00% | – |
| Q4 2020 | $222,000 | – | 13,372 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |